Trial reportJCO precision oncology2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Shivaani Kummar, Zihe Song, Kim A Reiss, James M Ford, Li Chen, Annah S Rolig, James A Zwiebel, Steven D Gore, Robert J Gray, Victoria Wang and 17 more
Abstract readClinical Trial, Phase II
In one paragraphTrial report in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
27 authors.
Shivaani KummarDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR.ORCID 0000-0001-6906-1627 Zihe SongDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Annah S RoligDivision of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Heath & Science University School of Medicine, Portland, OR.ORCID 0000-0001-7080-4352 James A ZwiebelInvestigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-4455-8789 Steven D GoreCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Victoria WangDana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
Lisa M McShaneBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206 Larry V RubinsteinBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9720-9737 David PattonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166 Jacob GrossCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-4245-1155 Donna BrunnquellCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0009-0000-6250-4210 Latifa F JacksonCenter for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-0949-978X Naoko TakebeCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-5790-4954 James V TricoliTreatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Barbara A ConleyCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684 Carlos L ArteagaUT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX.
Lyndsay N HarrisCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Alice P ChenDevelopmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-2919-4326 Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MNCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer CenterUG1CA233184 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ADAM M BRUFSKY, John Munn Kirkwood · 2019 to 2026
$7.7MUT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4MNCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233184NCI NIH HHS UG1 CA233302
6 · The paper itselfAbstract
purposeInhibition of WEE1, a tyrosine kinase responsible for G2 arrest, results in premature mitotic entry and double-strand DNA breaks. Adavosertib is a selective, ATP-competitive, and small-molecule WEE1 kinase inhibitor. In an adavosertib single-agent, Phase I trial, partial responses (PRs) were observed in patients with solid tumors carrying pathogenic variants (PVs) in PATIENTS AND
methodsEligible patients met criteria for the National Cancer Institute-Molecular Analysis for Therapy Choice master protocol and had a diagnosis of advanced
resultsThe ORR was 3.3% (90% CI, 0.2 to 14.9); the OS6 was 57.3% (90% CI, 41.9 to 72.7); the PFS6 was 23.4% (90% CI, 10.7 to 36.2). One PR (fallopian tube serous carcinoma) and six cases of stable disease (SD, >6 months) were observed. In patients with SD <6 months or progressive disease (nonresponders), significantly increased PI3K/AKT/mTOR signaling pathway gene transcripts suggested activation of this resistance mechanism. The primary reason for treatment discontinuation was disease progression. Common side effects included myelosuppression, fatigue, nausea, anemia, vomiting, and diarrhea.
conclusionIn heavily pretreated, advanced solid tumor patients with PV in
Indexed as
BRCA1 ProteinBRCA2 ProteinNeoplasmsPyrazinesPyrazolesAdultAgedFemaleHumansMaleMiddle AgedMutationPyrimidinonesadavosertibBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPyrazinesPyrazolesPyrimidinones
Identifiers
PMID42308463
PMCPMC13335521
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390